The group’s principal activities include designing, discovering and developing a new class of drugs. The group products sold under the trade names NNR Therapeutics(TM), Targacept(R), Inversine(R), Pentad(TM) and TRIDMAC(TM). The group operates from the United States. The total revenue of the group for the year 2006 was $27,538 (thousands).
